Investments

Neopharmed Gentili represents the spin-off of the primary care business of Mediolanum Farmaceutici Group and is a leading pharmaceutical company in the Italian market focused on branded prescription drugs in cardiovascular, neurology and allergo-respiratory therapeutic areas, with a portfolio of off-patent and mostly proprietary products. Its flexible and asset-light business model makes Neopharmed Gentili an attractive commercial platform with a proprietary, reliable, and specialized sales force of over 400 pharma representatives.